Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:NVO NASDAQ:PLTR NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVONovo Nordisk A/S$44.24-0.1%$39.95$35.12▼$81.44$197.71B0.7718.53 million shs9.69 million shsPLTRPalantir Technologies$135.26+0.1%$143.83$118.93▼$207.52$323.97B1.5244.29 million shs29.69 million shsUTHRUnited Therapeutics$566.800.0%$561.48$272.12▼$609.35$24.07B0.6407,451 shs403,913 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVONovo Nordisk A/S-0.18%-5.80%+9.30%-10.19%-33.93%PLTRPalantir Technologies+0.09%-0.54%-7.60%-0.09%+7.07%UTHRUnited Therapeutics-0.03%-2.57%-3.67%+19.06%+85.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVONovo Nordisk A/S$44.24-0.1%$39.95$35.12▼$81.44$197.71B0.7718.53 million shs9.69 million shsPLTRPalantir Technologies$135.26+0.1%$143.83$118.93▼$207.52$323.97B1.5244.29 million shs29.69 million shsUTHRUnited Therapeutics$566.800.0%$561.48$272.12▼$609.35$24.07B0.6407,451 shs403,913 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVONovo Nordisk A/S-0.18%-5.80%+9.30%-10.19%-33.93%PLTRPalantir Technologies+0.09%-0.54%-7.60%-0.09%+7.07%UTHRUnited Therapeutics-0.03%-2.57%-3.67%+19.06%+85.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNVONovo Nordisk A/S 2.13Hold$65.5648.20% UpsidePLTRPalantir Technologies 2.61Moderate Buy$195.1644.29% UpsideUTHRUnited Therapeutics 2.85Moderate Buy$619.429.28% UpsideCurrent Analyst Ratings BreakdownLatest PLTR, NVO, and UTHR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026NVONovo Nordisk A/S CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral5/11/2026PLTRPalantir Technologies Phillip SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price Target$190.00 ➝ $202.005/7/2026UTHRUnited Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$516.005/7/2026UTHRUnited Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$575.00 ➝ $735.005/7/2026PLTRPalantir Technologies Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/7/2026UTHRUnited Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$707.00 ➝ $701.005/6/2026PLTRPalantir Technologies CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$210.00 ➝ $225.005/6/2026PLTRPalantir Technologies ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$190.005/5/2026PLTRPalantir Technologies Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderperform$90.005/5/2026PLTRPalantir Technologies WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$230.005/5/2026PLTRPalantir Technologies DA DavidsonSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$180.00 ➝ $165.00(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNVONovo Nordisk A/S$46.80B4.22$4.68 per share9.45$7.12 per share6.21PLTRPalantir Technologies$4.48B72.45$0.69 per share195.71$3.57 per share37.89UTHRUnited Therapeutics$3.18B7.56$32.97 per share17.19$139.02 per share4.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNVONovo Nordisk A/S$15.51B$4.2610.3812.863.9437.23%63.31%22.19%8/5/2026 (Estimated)PLTRPalantir Technologies$1.63B$0.89151.9880.512.1443.67%28.34%23.57%8/3/2026 (Estimated)UTHRUnited Therapeutics$1.33B$27.0920.9217.611.8340.62%19.24%17.25%7/29/2026 (Estimated)Latest PLTR, NVO, and UTHR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026NVONovo Nordisk A/S$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billion5/6/2026Q1 2026UTHRUnited Therapeutics$7.00$5.82-$1.18$5.82$797.40 million$781.50 million5/4/2026Q1 2026PLTRPalantir Technologies$0.2774$0.33+$0.0526$0.34$1.54 billion$1.63 billion3/31/2026Q1 2026NVONovo Nordisk A/SN/A$1.0270N/A$1.69N/A$10.85 billion2/25/2026Q4 2025UTHRUnited Therapeutics$6.78$7.70+$0.92$7.70$814.80 million$790.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthNVONovo Nordisk A/S$1.753.96%+21.74%41.08%N/APLTRPalantir TechnologiesN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNVONovo Nordisk A/S0.590.790.56PLTRPalantir TechnologiesN/A6.916.91UTHRUnited TherapeuticsN/A4.794.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNVONovo Nordisk A/S11.54%PLTRPalantir Technologies45.65%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipNVONovo Nordisk A/S0.07%PLTRPalantir Technologies9.53%UTHRUnited Therapeutics8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNVONovo Nordisk A/S69,5054.47 billion4.46 billionOptionablePLTRPalantir Technologies4,4292.40 billion2.17 billionOptionableUTHRUnited Therapeutics1,40042.45 million38.80 millionOptionablePLTR, NVO, and UTHR HeadlinesRecent News About These CompaniesUnited Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 SharesMay 19 at 5:09 PM | marketbeat.comUnited Therapeutics Corporation (UTHR) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 19 at 4:03 PM | seekingalpha.comUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of StockMay 19 at 4:04 AM | americanbankingnews.comUnited Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026May 18 at 4:15 PM | businesswire.comHC Wainwright Issues Pessimistic Outlook for UTHR EarningsMay 18 at 1:09 AM | americanbankingnews.comHC Wainwright Has Negative Estimate for UTHR Q2 EarningsMay 18 at 1:08 AM | marketbeat.comUnited Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026May 17 at 2:15 PM | businesswire.comLeuthold Group LLC Buys 3,126 Shares of United Therapeutics Corporation $UTHRMay 17 at 6:49 AM | marketbeat.comUnited Therapeutics Corporation $UTHR Stock Position Decreased by Thrivent Financial for LutheransMay 17 at 5:31 AM | marketbeat.com5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings CallMay 16, 2026 | uk.finance.yahoo.comAustralianSuper Pty Ltd Sells 82,261 Shares of United Therapeutics Corporation $UTHRMay 16, 2026 | marketbeat.comFY2030 EPS Forecast for United Therapeutics Cut by AnalystMay 16, 2026 | americanbankingnews.comUnited Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical TrialMay 15, 2026 | businesswire.comHC Wainwright Issues Pessimistic Estimate for UTHR EarningsMay 15, 2026 | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of StockMay 15, 2026 | insidertrades.comSpace-Based Pulmonary Drug Formulation Might Change The Case For Investing In United Therapeutics (UTHR)May 14, 2026 | finance.yahoo.comCPRX or UTHR: Which Is the Better Value Stock Right Now?May 14, 2026 | zacks.comUnited Therapeutics (NASDAQ:UTHR) Director Nilda Mesa Sells 258 SharesMay 14, 2026 | insidertrades.comPacer Advisors Inc. Trims Holdings in United Therapeutics Corporation $UTHRMay 14, 2026 | marketbeat.comSwiss Life Asset Management Ltd Purchases 4,134 Shares of United Therapeutics Corporation $UTHRMay 14, 2026 | marketbeat.comAmeritas Advisory Services LLC Boosts Stake in United Therapeutics Corporation $UTHRMay 14, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?By Thomas Hughes | April 29, 2026Palantir Is Down 30%: Noise? Or a Signal to Accumulate?By Chris Markoch | April 28, 2026What the FDA's Latest Proposal Means for Lilly, Novo, and HimsBy Leo Miller | May 7, 2026Palantir Drops After a Blowout Q1—What Investors Should KnowBy Chris Markoch | May 5, 2026Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusBy Jessica Mitacek | May 8, 2026PLTR, NVO, and UTHR Company DescriptionsNovo Nordisk A/S NYSE:NVO$44.24 -0.04 (-0.09%) Closing price 05/19/2026 03:59 PM EasternExtended Trading$44.34 +0.10 (+0.23%) As of 05/19/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.Palantir Technologies NASDAQ:PLTR$135.26 +0.12 (+0.09%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$134.82 -0.44 (-0.32%) As of 05/19/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates under the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.United Therapeutics NASDAQ:UTHR$566.80 -0.19 (-0.03%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$562.27 -4.53 (-0.80%) As of 05/19/2026 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas HIVE Weaponizes Power for an AI Pivot Why Home Depot’s Sell-Off Could Become a Huge Opportunity Brady Corp Wires Up a Massive AI-Powered Breakout AAPL: Forget the iPhone—Services Will Drive the Next Phase of Growth Nebius Group Pulls Back 9% After a Downgrade Despite Strong Earnings A Deep Dive Into NVIDIA’s Latest Portfolio Moves The $132 Billion Infrastructure Pivot You Might Have Missed The Pentagon's AI Pivot Supercharges Defense Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
